Exploring Nemvaleukin Alfa Monotherapy & in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Time: 11:30 am
day: Conference Day Two
Details:
- Outlining nemvaleukin as a novel engineered cytokine
- Revealing the design to selectively bind to intermediate-affinity interleukin-2 receptor (IL-2R) for preferential activation and expansion of tumor-killing CD8+ T cells and natural
- killer (NK) cells, with minimal expansion of regulatory T cells (Tregs)
- Discussing the potential to reduce native IL-2’s toxicities, thus allowing greater tolerability and efficacy than other IL-2 molecules have shown in the past
